Skip to content

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

ISSN 1873-3441

2 papers in the library · 80 citations · publishing 2009-2025

Papers

Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V June 1, 2009 Zeynep S Teksin, Insong J Lee, Noble N Nemieboka et al. 76 citations

Salvinorin A, a potent hallucinogen from Salvia divinorum, is rapidly eliminated after intraperitoneal dosing in rats, with a half-life of 75 minutes and a clearance of 26 L/h/kg. Its distribution is extensive (47.1 L/kg), but brain levels are low (brain-to-plasma ratio 0.050) and the brain half-life is only 36 minutes. In cell studies, salvinorin A is transported by P-glycoprotein and metabolized by several enzymes, including CYP2D6, CYP1A1, CYP2C18, CYP2E1, and UGT2B7. These findings align with the compound's fast onset and short duration of action.

Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V February 1, 2025 Octavio E Fandiño, Aaron R J Hutton, Chunyang Zhang et al. 4 citations

Hydrogel-forming microarray patches (HF-MAPs) can deliver small doses of the psychedelic compounds N,N-dimethyltryptamine (DMT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescaline (MES) through the skin. In tests using excised neonatal porcine skin, a reservoir containing polyethylene glycol 400 enabled permeation of 60.71% for DMT, 59.61% for 5-MeO-DMT, and 41.85% for MES. Pharmacokinetic studies in rats showed that DMT delivered via HF-MAP had a significantly greater area under the curve (7186 ± 1296 ng/mL*h) compared to intramuscular injection (1803 ± 53.25 ng/mL*h), with a relative bioavailability of about 72%. This suggests HF-MAP technology could reduce dosing frequency for DMT microdosing.